ARVs

1.

Global Fund will 'donate' $5 million to Venezuela to provide treatment for HIV

2 Oct 2018
The bulk of the funds will be paid into the PAHO Strategic Fund to purchase ARVs
The money will come from funds designated for portfolio optimization

The Global Fund will donate 5.0 million U.S. dollars to finance the procurement of critical health products for Venezuela, which is in the midst of a severe economic and health crisis.

3.

Poor stock management contributed to theft of medicines purchased with Global Fund grants to C.A.R., OIG says

20 Feb 2018
There were ongoing leakages of ACTs over a 17-month period
1.

Political instability, decreasing resources and a resurgent malaria epidemic: A challenging environment for Global Fund grants in Burundi

6 Feb 2018
Malaria incidence doubled between 2014 and 2016
2.

Ukraine starts transition away from Global Fund support without a detailed transition plan, OIG says

6 Feb 2018
Audit gives Ukraine a mixed report card
1.

Global Fund Board approves a second batch of grants for 2017-2019

28 Nov 2017
Twenty funding requests yielded 32 grants
10.

Audit of Global Fund grants to Mali reveals significant progress in financial management and quality of services

28 Nov 2017
However, there are problems with drug expiries, stock-outs and delays in the supply chain
2.

Catastrophe in Venezuela imperils the achievement of the Global Fund Strategy (2017-2022), says new report

16 Oct 2017
Calls on Global Fund to lead a comprehensive regional response

Venezuela is in the middle of an unprecedented, state-made, complex humanitarian emergency.  The public health crisis, which is just a symptom of the larger unraveling that is unfolding, has reached extreme levels. Essentials like soap and gloves have vanished from hospital floors. Life-saving medications are sometimes only available on the black market and cost half a month’s wages.

3.

Global Fund to benefit from “breakthrough” ARV pricing agreement

3 Oct 2017
State-of-the-art fixed dose combination regimen will cost $75 per patient per year

In what has been hailed as a “breakthrough” and a “game changer,” a pricing agreement between the Bill and Melinda Gates Foundation and two generic drug companies will result in significant savings in the cost of antiretrovirals (ARVs). As a result of the agreement, starting in 2018 a state-of-the-art fixed dose combination ARV regimen will be available in 92 developing nations at a maximum cost of $75 per patient per year.

3.

OIG audit of two Global Fund grants to Guinea finds significant weaknesses in supply chain management

5 Sep 2017
Improvements also required in grant implementation
Nevertheless, Guinea has made significant progress in the fight against the diseases

Although Guinea has made significant progress in the fight against the three diseases, despite a challenging operating environment, there are significant weaknesses in supply chain management and there are areas related to managing grant implementation that require improvement. These were the findings of an audit of Global Fund grants to Guinea conducted by the Office of the Inspector General (OIG).

8.

In brief: Important HIV-related developments

8 Aug 2017

Several important HIV-related announcements were made in the last few weeks. We provide short summaries.

“The scales have tipped”

Pages

Subscribe to ARVs